InjectionMRP Under Process
Official PMBI MRP is being updated for catalog code 2618.
Locate Jan Aushadhi KendraClinical Overview
Panitumumab Infusion (100mg, 400mg) is a recombinant, fully human IgG2 monoclonal antibody on the WHO Model List of Essential Medicines that binds specifically to the human Epidermal Growth Factor Receptor (EGFR / HER1). It competitively prevents binding of endogenous EGF and TGF-alpha, halting EGFR dimerization, receptor autophosphorylation, and downstream pro-proliferative intracellular cascades. Indicated for wild-type KRAS and NRAS (exon 2, 3, and 4) metastatic colorectal carcinoma (mCRC), as first-line therapy with FOLFOX, or as monotherapy following progression on oxaliplatin, irinotecan, and fluoropyrimidines.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administer intravenously only through an in-line low-protein-binding 0.2-micron filter over 60 minutes (doses <=1000 mg) or 90 minutes (doses >1000 mg) every 14 days (6 mg/kg). Do NOT administer as an IV push or bolus. Premedicate with antihistamines and corticosteroids.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Papulopustular acneiform skin rash, paronychia, pruritus, erythema, diarrhea, hypomagnesemia, fatigue, nausea. Rare/Severe: Fatal infusion reactions, pulmonary fibrosis / interstitial lung disease, ocular keratitis, and severe hypomagnesemia / hypokalemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Dermatologic and soft tissue toxicity (severe acneiform rash occurs in >90% of patients; withhold or reduce dose for grade 3+ toxicity); apply prophylactic moisturizers and sunscreens. Black Box Warning: Ineffective in patients with mutated RAS (KRAS/NRAS) colorectal tumors; genetic testing for wild-type RAS is mandatory prior to therapy. Monitor serum magnesium and calcium weekly.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.